On January 4, 2023 IntoCell reported the signing of a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics SA (NYSE: ADCT) (Press release, IntoCell, JAN 4, 2023, View Source [SID1234625840]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the agreement, IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) platform technologies, will provide proprietary drug-linkers developed using their proprietary Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) system and payload modification technology (PMT). ADC Therapeutics, a commercial-stage biotechnology company developing next-generation ADCs, will conjugate its antibodies to IntoCell’s drug-linker and perform in vitro, in vivo, and toxicology experiments.
Upon successful completion of the evaluation, ADC Therapeutics will have an option to license the technology to develop ADCs for up to six targets for global development and commercialization. IntoCell reserves all global rights for its platform technologies beyond ADC development for targets reserved by ADC Therapeutics and will receive a fee upon signing of the MTA. For each target option exercised by ADCT, IntoCell is also entitled to receive a target selection fee, potential development, regulatory, and commercial milestone payments, as well as royalties in the future upon successful achievement of each applicable milestone.
"We are pleased to be collaborating with ADC Therapeutics, one of the leading companies in the ADC area. We hope to leverage ADC Therapeutics’ experience with the development and commercialization of its own ADC ZYNLONTA," said Tae Kyo Park, Founder and CEO of IntoCell. "IntoCell’s linker is highly stable and soluble, and our modified payload has the potential to substantially improve the therapeutic window of various payload classes. We are excited to see how our drug-linker technologies will perform with ADC Therapeutics’ antibodies."
"IntoCell’s innovative platform technologies have the potential to be valuable additions to ADC Therapeutics’ toolbox as we continue to maximize our ADC platform," said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics. "We look forward to evaluating our antibodies with IntoCell’s drug-linker technologies in the pursuit of developing differentiated ADCs."
IntoCell was advised by PharmaVentures Ltd., a UK-based premier transaction advisory firm, for this collaboration and the ongoing partnering efforts for IntoCell’s platform technologies and their lead programme, B7-H3 ADC